Assessment the of Amplification HER-2/neu Gene by Chromogenic In Situ Hybridization (CISH) Compared to Immunohistochemistry (IHC) Method in Gastric Cancer

Document Type : Original Article

Authors

1 Professor of Pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran

2 Fellowship of Molecular Pathology and Cytogenetics, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran

3 Fellow of Molecular Pathology and Cytogenetics, Shiraz University of Medical Sciences, Shiraz, Iran

4 Student Research Committee, Gastrointestinal and Fatty Liver Research Center, Faculty of Medical Sciences, Mashhad University of Medical Sciences, Mashhad, IR Iran

5 Resident of pathology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, IR Iran

Abstract

Background: Gastric cancer has a high mortality rate and often has a poor treatment outcome. The HER2/neu gene target therapy has been known as a potential way for treatment.

Objectives: The goal of our study was assessment the relation between chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) methods in determining the best diagnostic method for gastric cancer.

Methods: In this historical cohort study, 50 gastric cancer samples were analyzed by CISH and IHC. The relation between clinicalpathological parameters of HER2/neu was also analyzed. Alive patients were followed from 2009 through 2012 for the main outcomes(mortality). The results of these two methods, in terms of sex, age, tumor size, grading, staging, tumor location, metaplasia, presence of necrosis and ulceration, vascular invasion, the TNM system, mucin or signet producing adenocarcinoma cells and patient survival rates were compared.

Results: There was no significant difference between IHC and CISH regarding the sex, age, tumor size, grading, staging, tumor location, metaplasia, presence of necrosis and ulceration, vascular invasion, the TNM system, mucin or signet producing adenocarcinoma cells and patient survival rates. Comparison of TNMscores by these two methods showed no significant relationship between IHC and staging, but a statistically significant difference between CISH and different N staging, (P < 0.05) was assessed.

Conclusions: Comparison between IHC and CISH showed the only significant relationship between CISH and different N staging.Therefore, low amplified CISH was a better diagnostic method for gastric cancer, compared to low expression in IHC.

Keywords

Open Access Policy: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/

References

1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol. 2009;472:467-77. doi: 10.1007/978-1-60327-492- 0_23. [PubMed: 19107449].
https://doi.org/10.1007/978-1-60327-492-0_23
PMid:19107449
 
2. Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556-63. [PubMed: 19073863].
https://doi.org/10.1093/annonc/mdn642
PMid:19073863
 
3. Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med. 2009;12(6):576-83. [PubMed: 19877751].
 
4. Bozzetti C, Negri FV, Lagrasta CA, Crafa P, Bassano C, Tamagnini I, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer. 2011;104(9):1372-6. [PubMed: 21487407].
https://doi.org/10.1038/bjc.2011.121
PMid:21487407 PMCid:PMC3101935
 
5. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.Histopathology. 2008;52(7):797-805. [PubMed: 18422971].
https://doi.org/10.1111/j.1365-2559.2008.03028.x
PMid:18422971
 
6. Carter WB, Hoying JB, Boswell C, Williams SK. HER2/neu overexpression induces endothelial cell retraction. Int J Cancer. 2001;91(3):295-9. [PubMed: 11169950].
https://doi.org/10.1002/1097-0215(200002)9999:9999<::AID-IJC1061>3.0.CO;2-Y
PMid:11169950
 
7. Tanner M, Gancberg D, Di Leo A, Larsimont D, Rouas G, Piccart MJ, et al. Chromogenic in Situ Hybridization. Am J Pathol. 2000;157(5):1467-72.
https://doi.org/10.1016/S0002-9440(10)64785-2
PMid:11073807
 
8. Reisenbichler ES, Horton D, Rasco M, Andea A, Hameed O. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol. 2012;137(1):102-10. [PubMed: 22180483].
https://doi.org/10.1309/AJCPLNHINN9O6YSF
PMid:22180483
 
9. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273-8. [PubMed: 15668283].
https://doi.org/10.1093/annonc/mdi064
PMid:15668283
 
10. Madrid MA, Lo RW. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status. Breast Cancer Res. 2004;6(5):R593-600. [PubMed: 15318940].
https://doi.org/10.1186/bcr915
PMid:15318940 PMCid:PMC549176
 
11. Lee KE, Lee HJ, Kim YH, Yu HJ, Yang HK, Kim WH, et al. Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer. Jpn J Clin Oncol. 2003;33(4):173-9. [PubMed: 12810831].
https://doi.org/10.1093/jjco/hyg039
PMid:12810831
 
12. Aoyagi K, Kohfuji K, Yano S, Murakami N, Miyagi M, Takeda J, et al. Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma. Kurume Med J. 2001;48(3):197-200. [PubMed: 11680933].
https://doi.org/10.2739/kurumemedj.48.197
PMid:11680933
 
13. Thor A. HER2-a discussion of testing approaches in the USA.Ann Oncol. 2001;12 Suppl 1:S101-7. [PubMed: 11521714].
https://doi.org/10.1093/annonc/12.suppl_1.S101
PMid:11521714
 
14. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, et al. Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94(11):852-4. [PubMed: 12048273].
https://doi.org/10.1093/jnci/94.11.852
PMid:12048273
 
15. Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94(11):855- 7. [PubMed: 12048274].
https://doi.org/10.1093/jnci/94.11.855
PMid:12048274
 
16. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124(7):966-78. [PubMed: 10888772].
https://doi.org/10.5858/2000-124-0966-PFIBC
PMid:10888772
 
17. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113(6):852-9. [PubMed: 10874886].
https://doi.org/10.1309/VACP-VLQA-G9DX-VUDF
PMid:10874886
 
18. Ridolfi RL, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13(8):866-73. [PubMed: 10955453].
https://doi.org/10.1038/modpathol.3880154
PMid:10955453
 
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719-26. [PubMed: 11821453].
https://doi.org/10.1200/JCO.2002.20.3.719
PMid:11821453
 
20. Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. 2003;42(4):337-47. [PubMed: 12653945].
https://doi.org/10.1046/j.1365-2559.2003.01598.x
PMid:12653945
 
21. Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol. 2002;15(6):657-65. [PubMed: 12065780].
https://doi.org/10.1038/modpathol.3880582
PMid:12065780
 
22. Kato N, Itoh H, Serizawa A, Hatanaka Y, Umemura S, Osamura RY. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Pathol Int. 2010;60(7):510-5. [PubMed: 20594272]. 23. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-9. [PubMed: 18441328].
https://doi.org/10.1111/j.1440-1827.2010.02553.x
PMid:20594272
 
23. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51(8):1371-9. [PubMed: 16868827].
https://doi.org/10.1007/s10620-005-9057-1
PMid:16868827
 
24. Todorovic-Rakovic N, Jovanovic D, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. Comparison between immunohistochemistry and chromogenic in situ hybridization in assessing HER-2 status in breast cancer. Pathol Int. 2005;55(6):318-23. [PubMed: 15943788].
 
25. Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, et al. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer. 2013;13:351. [PubMed: 23875536].
https://doi.org/10.1186/1471-2407-13-351
PMid:23875536 PMCid:PMC3729815
Razavi International Journal of Medicine
Volume 6, Issue 1
January 2018
Pages 21-27

Files

Share

How to cite

Statistics